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Identity 
Other names: BTF; KIAA0164; bK211L9.1 
HGNC (Hugo): BCLAF1 
Location: 6q23.3 
Local order: Orientation on minus strand, flanked by 
FAM54A and MAP7 (according to GeneLoc and NCBI 
Map Viewer). 
Note: BCLAF1 was originally identified as a protein 
partner for adenoviral E1B 19K. Forced expression of 
BCLAF1 causes cell death which is reversed in the 
presence of anti-apoptotic BCL-2. BCLAF1 was 
reported to associate in vitro with BCL-2 and BCL2L1. 
BCLAF1 was also reported to bind DNA and repress 
transcription. Taken together, these findings suggested 
a role for BCLAF1 in apoptotic signalling and 
transcriptional repression (Kasof et al., 1999). 
Subsequent studies using BCLAF1-depleted or Bclaf1-
deficient cells do not reveal a critical role for BCLAF1 
in death signalling (Ziegelbauer et al., 2009; 
McPherson et al., 2009). Recent studies have suggested 
roles for BCLAF1 in processes of RNA metabolism 
(Bracken et al., 2008; Sarras et al., 2010), KSHV viral 
production (Ziegelbauer et al., 2009), lung 
development and T cell activation (McPherson et al., 
2009; Kong et al., 2011). 
DNA/RNA 
Description 
The BCLAF1 gene is composed of 13 exons and spans 
32989 bases. 
Transcription 
Two transcripts 5 kb and 3 kb in length are 
predominantly detected, however additional variant 
transcripts have been described with alternative 





At least 4 isoforms are generated by alternative 
splicing. Two predominant BCLAF1 forms were 
initially described: a longer isoform 920 amino acids n 
length with a predicted molecular mass of 106 kDa, and
a smaller isoform missing 49 amino acids (residues 
797-846) with a predicted molecular mass of 101 kDa 
(Kasof et al., 1999). Residues 110-126 exhibit 88% 
homology to the bZIP DNA binding domain (Kasof et 
al., 1999). Residues 522-531 exhibit 80% homology to 
the Myb DNA binding domain (Kasof et al., 1999). 
Functional evidence for both of these domains remains 
to be shown. The N-terminal region (residues 3-161) of 
BCLAF1 is arginine- and serine-rich (RS domain). The 
C-terminal region (residues 512-913) is 59% similar to 
the C-terminal region of thyroid hormone receptor 
associated protein 3 (THRAP3/TRAP150). 
Expression 
BCLAF1 is ubiquitously expressed, with high steady-
state mRNA levels in skeletal muscle,  
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Protein domains in BCLAF1L and BCLAF1S isoforms. 
 
haematopoietic cells, and various other cell lineages 
(Kasof et al., 1999; McPherson et al., 2009). Steady-
state levels of BCLAF1 protein fluctuate in a temporal 
and cell-lineage dependent fashion during development 
(McPherson et al., 2009). 
Localisation 
Bclaf1 is concentrated in punctate foci interspersed 
through the nucleus. In the presence of E19K and 
conditions which trigger apoptosis, the nuclear 
distribution of Bclaf1 appears to concentrate at the
nuclear periphery or envelope (Kasof et al., 1999; 
Haraguchi et al., 2004). 
Bclaf1 was identified as a protein component of 
interchromatin granular clusters, subnuclear structures 
that appear to serve as repositories for pre-mRNA 
splicing factors (Misteli and Spector, 1998; Sutherland 
et al., 2001; Saitoh et al., 2004). 
Function 
The exact molecular function of BCLAF1 remains to 
be defined. BCLAF1 was originally identified as 
having properties of a death-inducing transcriptional 
repressor (Kasof et al., 1999). Several subsequent 
studies have expanded on the link between BCLAF1, 
transcription and apoptosis. Depletion of BCLAF1 was 
reported to render cells resistant to ceramide-induce  
apoptosis (Renert et al., 2009). Protein kinase C delta-
mediated transactivation of p53 transcription has been 
shown to occur through the stimulation of BCLAF1 to 
co-occupy a core promoter element in the TP53 
promoter (Liu et al., 2007). A role for Bclaf1 in lung 
development and T cell homeostasis was demonstrated 
in Bclaf1-deficient mice (McPherson et al., 2009). 
Bclaf1 was shown to be required for the proper spatial 
and temporal organization of smooth muscle lineage 
cells during the saccular stage of lung development. 
Bclaf1 was also shown to be critical for T cell 
activation. The phenotype of these mice could not be 
explained by a defect in apoptosis, furthermore Bclaf1-
deficient cells displayed no defect in cell death 
following exposure to various apoptotic stimuli. 
Recent studies have implicated BCLAF1 in processes 
linked to RNA metabolism. BCLAF1 contains an RS 
domain, a feature of many factors that facilitate pr -
mRNA splicing and mRNA processing. BCLAF1 was 
found to be a component of ribonucleoprotein 
complexes (Merz et al., 2007; Sarras et al., 2010).  
Bclaf1-deficient cells were found to exhibit altered 
preferences for alternative splicing of a model substrate 
(Sarras et al., 2010). BCLAF1 was found associated 
with SkIP, TRAP150 and Pinin in a complex known as 
SNIP1. SNIP1 was found to regulate cyclin D1 mRNA 
processing by facilitating the recruitment of the RNA 
processing factor U2AF65 to cyclin D1 mRNA 
(Bracken et al., 2008). 
BCLAF1 has been shown to complex with the RNA 
export factor TAP/NXF1 (Sarras et al., 2010). This 
property has also recently been reported for TRAP150, 
a protein showing structural similarity to BCLAF1 tha  
also is found in ribonucleoprotein complexes (Lee et 
al., 2010). TRAP150 has been shown to promote pre-
mRNA splicing of reporter substrates and promotes 
mRNA decay in a manner that is independent of 
nonsense-mediated decay of mRNA (Lee et al., 2010). 
Regulation 
Sirt1 has been shown to exert transcriptional control of 
BCLAF1 at the promoter level (Kong et al., 2011). 
Sirt1 was found to form a complex with the histone 
acetyltransferase p300 and NF-kB transcription factor 
Rel-A, bind the BCLAF1 promoter and suppress 
BCLAF1 transcription via H3K56 deacetylation (Kong 
et al., 2011). 
BCLAF1 protein levels fluctuate according to cell 
cycle position, with levels highest during the G1 phase, 
but lower during S and G2 phases (Bracken et al., 
2008). BCLAF1 protein levels also fluctuate in a cell-
lineage and temporal manner during differentiation of 
certain tissues and organs (McPherson et al., 2009). 
Several studies have determined that Bclaf1 is 
extensively phosphorylated, although the functional 
significance of this modification is unclear. BCLAF1 
has been proposed as a substrate of GSK-3 kinase 
(Linding et al., 2007). Vasopressin action in kidney 
cells has been reported to simulate BCLAF1 
phosphorylation (Hoffert et al., 2006). 
BCLAF1 has been shown to be one of the cellular 
targets for microRNAs (miRNAs) encoded by Kaposi's 
sarcoma-associated herpesvirus (KSHV). KSHV 
triggers certain acquired immune deficiency syndrome-
related malignancies such as Kaposi's sarcoma, primary 
effusion lymphoma and variants of multicentric 
Castleman disease. A miRNA cluster within the KSHV 
genome is expressed during viral latency. During 
induction of lytic KSHV growth, inhibition of miRNAs 
was associated with increased BCLAF1 expression and 
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decreased KSHV virion production (Ziegelbauer et al., 
2009). 
Interactions 
E1B 19K. By yeast two-hybrid analysis, BCLAF1 was 
shown to directly interact with adenoviral E1B 19K via
a BH3 domain and another region immediately 
adjacent to BH3 in E1B 19K (Kasof et al., 1999). In 
vitro binding assays reported BCLAF1 associates with 
BCL-2 and BCL2L1. 
emerin. By yeast-two hybrid analysis and microtiter 
well binding assays, BCLAF1 was shown to directly 
interact with emerin, a nuclear membrane protein. 
Mutations that result in a loss of functional emerin 
cause X-linked recessive Emery-Dreifuss muscular 
dystrophy. The residues of emerin required for binding 
to BCLAF1 mapped to two regions that flank its lamin-
binding domain. Two disease-causing mutations in 
emerin, S54F and Delta95-99, disrupted binding to 
BCLAF1. BCLAF1 and emerin were observed to co-
localize in the vicinity of the nuclear envelope 
following induction of apoptosis by Fas antibody 
(Haraguchi et al., 2004). 
MAN1. The C-terminal domain of MAN1, a nuclear 
inner membrane protein that inhibits Smad signaling 
downstream of transforming growth factor beta, was 
observed to bind BCLAF1, as well as the 
transcriptional regulators GCL, and barrier-to-
autointegration factor (BAF) (Mansharamani and 
Wilson, 2005). 
Factors that participate in RNA metabolism. 
BCLAF1 and TRAP150 have been identified to be 
protein components of ribonucleoprotein complexes 
that participate in pre-mRNA splicing and other mRNA 
processing events (Merz et al., 2007; Sarras et al., 
2010; Lee et al., 2010). Both BCLAF1 and TRAP150 
have been reported to reside in protein complexes that 
contain the mRNA export factor NXF1/TAP (Sarras et 
al., 2010; Lee et al., 2010). Both BCLAF1 and 
TRAP150, together with Pinin and SkIP, have been 
found in a protein complex that regulates cyclin D1
mRNA stability. 
Homology 
BCLAF1 shares amino acid similarity (48% overall 
identity) with TRAP150 in their C-terminal domains. 
Both proteins also contain RS-rich tracts within their 
N-termini (Lee et al., 2010). 
Mutations 
Note 
BCLAF1 is located at chromosome 6q23 , a region that 
has been reported to exhibit a high frequency of 
deletions in tumours, such as lymphomas and 
leukemias. BCLAF1 has observed to be absent in Raji 
cells, derived from Burkitt's lymphoma, which has 
deletions in 6q (Kasof et al., 1999). A role for the loss 
of BCLAF1 in neoplastic transformation remains to be 
determined and may be coincidental. 
Implicated in 
X-linked recessive Emery-Dreifuss 
muscular dystrophy 
Note 
Bclaf1 has also recently been identified as a binding 
partner for emerin, a nuclear membrane protein that is 
mutated in X-linked recessive Emery-Dreifuss 
muscular dystrophy. Disease mutations in emerin were 
found to disrupt the interaction of emerin with 
BCLAF1 (Haraguchi et al., 2004). 
Disease 
Emerin is encoded by the EMD gene located on human 
X-chromosome, which when mutated, gives rise to the 
X-linked form of Emery-Dreifuss muscular dystrophy 
(Bione et al., 1994). Emerin is a lamin A/C binding 
protein that participates in nuclear envelope mechani s 
which impact chromosome segregation, gene 
expression and muscle differentiation (Liu et al., 2003; 
Frock et al., 2006). 
Choroid plexus papillomas 
Note 
Up-regulation of BCLAF1 was observed in seven cases 
of choroid plexus papilloma cells compared to eight 
cases of normal choroid plexus epithelial cells 
(Hasselblatt et al., 2009). 
Disease 
Choroid plexus papillomas are rare intraventricular 
papillary neoplasms, typically in children and young 
adults. 
Non-Hodgkin's lymphoma (NHL) 
Note 
An association of BCLAF1 single nucleotide 
polymorphisms (tagSNPs rs797558 and rs703193, P = 
0.0097) with NHL was made following genotyping of 
441 newly diagnosed NHL cases and 475 frequency-
matched controls (Kelly et al., 2010). 
Disease 
Non-Hodgkin's lymphoma refers to several subtypes of 
lymphoma that are distinct from Hodgkin's lymphoma, 
such as Mantle cell lymphoma, diffuse large B cell 
lymphoma and follicular lymphoma (Sawas et al., 
2011). 
Chondromyxoid fibroma (CMF) 
Note 
No changes in BCLAF1 were found in 43 samples of 
CMF (Romeo et al., 2010). 
Disease 
Chondromyxoid fibroma (CMF) is an uncommon 
benign cartilaginous tumor of bone usually occurring i  
adolescents (Ralph, 1962; Romeo et al., 2009). CMF is 
associated with recurrent rearrangements of 
chromosome bands 6p23-25, 6q12-15, and 6q23-27. 
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